Joseph J. Wolk, Executive Vice President and Chief Financial Officer of Johnson & Johnson (NYSE:JNJ), recently sold shares of the company’s stock. According to a recent SEC filing, Wolk sold 13,015 shares of Johnson & Johnson common stock on February 7, 2025, at an average price of $153.89, totaling approximately $2,002,878.
Prior to the sale, Wolk exercised stock options to acquire the same number of shares at a price of $100.06 per share. Following these transactions, Wolk holds no shares directly, but retains indirect ownership of 68,835 shares through a spousal lifetime access trust and 2,113 shares via a 401(k) plan. The company has maintained dividend payments for 55 consecutive years, demonstrating strong financial stability. Discover more insights about JNJ’s financial health and growth potential with InvestingPro’s comprehensive research report, available along with 8 additional ProTips.
In other recent news, Johnson & Johnson is set to sell its stroke care business, Cerenovus, for a valuation of over $1 billion as part of a restructuring plan for its medical technology division. This comes as the company continues to restructure its medical technology division, with the sale of Cerenovus marking the latest step in this ongoing strategy. Additionally, Guggenheim maintained a neutral rating on Johnson & Johnson but increased the stock’s price target from $162.00 to $166.00, following the company’s fourth-quarter 2024 results which reported sales of $22.5 billion and earnings per share (EPS) of $2.04.
Similarly, Barclays (LON:BARC) analyst Matt Miksic increased the price target for Johnson & Johnson shares to $166, while maintaining an equal weight rating on the stock. Johnson & Johnson delivered solid results in the fourth quarter, with the pharmaceutical division, particularly the Oncology segment, showing strength. On the other hand, Bernstein SocGen Group adjusted its outlook on Johnson & Johnson stock, reducing the price target to $158 from $160 while maintaining a market perform rating. The adjustment followed Johnson & Johnson’s release of its fourth-quarter results and future guidance, which presented a mixed picture of the company’s performance and expectations.
These are recent developments that investors need to be aware of as they provide valuable insights into the company’s financial health and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.